Innovative Molecules Advances Adibelivir into Phase 2 for HSV-Mediated Diseases

Innovative Molecules GmbH, a German clinical-stage biotech company, has completed its Phase 1 clinical development program and advanced adibelivir (IM-250) into Phase 2 development.

Adibelivir is an oral selective helicase primase inhibitor being developed for the treatment of herpes simplex virus (HSV)-mediated diseases.

What was completed in Phase 1?

The Phase 1 program included four clinical studies:

• IM-101 – Phase 1a single-ascending dose study in healthy volunteers
• IM-102 – Multiple-ascending dose study in healthy volunteers
• IM-103 – Food-effect study in healthy volunteers
• IM-202 (Phase 1b) – Part of a combined Phase 1b/2a study in patients with genital herpes

Across these trials, oral adibelivir showed a clinical profile that supports progression into the Phase 2a, efficacy-focused portion of IM-202.

Why this matters?

Current antiviral therapies for HSV rely largely on nucleoside analogs, which:

• Do not eliminate latent virus
• Require frequent dosing
• May show reduced effectiveness in resistant strains

Selective helicase primase inhibitors represent a new antiviral class designed to directly block viral DNA replication.

Adibelivir’s advancement suggests potential for:

• Improved antiviral potency
• Better convenience with oral dosing
• Expanded options for patients with recurrent or difficult-to-treat HSV infections

Company perspective

Florian Vogel, CEO of Innovative Molecules:

With the successful completion of our Phase 1 program, we have achieved a critical development milestone for adibelivir. This validates our clinical strategy and forms a strong foundation for transition into the next stage of clinical development.

About adibelivir (IM-250)

• Oral selective helicase primase inhibitor
• Designed for HSV-mediated diseases
• Positioned as a next-generation antiviral candidate

About Innovative Molecules

Innovative Molecules GmbH is a Munich-based biotechnology company developing transformative therapies for herpes infections. Its pipeline focuses on novel antivirals for severe and underserved patient populations, with adibelivir as its lead program.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!